Equities research analysts expect that KemPharm Inc (NASDAQ:KMPH) will post earnings per share of ($0.28) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for KemPharm’s earnings, with estimates ranging from ($0.29) to ($0.27). KemPharm posted earnings of ($0.94) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 70.2%. The company is expected to report its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that KemPharm will report full-year earnings of ($1.25) per share for the current year, with EPS estimates ranging from ($1.28) to ($1.21). For the next financial year, analysts anticipate that the company will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.35) to $0.32. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover KemPharm.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.09.
A number of research firms recently weighed in on KMPH. ValuEngine upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of KemPharm in a research note on Thursday, September 5th. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Friday, October 25th. Finally, Roth Capital lowered shares of KemPharm from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $4.25 to $1.05 in a research note on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $1.89.
NASDAQ KMPH traded down $0.02 during trading hours on Friday, hitting $0.50. The company’s stock had a trading volume of 58,300 shares, compared to its average volume of 175,182. KemPharm has a 52 week low of $0.45 and a 52 week high of $3.00. The company has a market capitalization of $18.62 million, a PE ratio of -0.20 and a beta of 1.39. The company’s 50-day simple moving average is $0.63 and its two-hundred day simple moving average is $1.17.
In other news, CEO Travis C. Mickle purchased 50,000 shares of KemPharm stock in a transaction dated Tuesday, September 24th. The stock was purchased at an average cost of $0.79 per share, for a total transaction of $39,500.00. Following the transaction, the chief executive officer now directly owns 1,713,117 shares of the company’s stock, valued at $1,353,362.43. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have bought a total of 73,000 shares of company stock valued at $58,237 over the last 90 days. Company insiders own 14.90% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wedbush Securities Inc. grew its position in shares of KemPharm by 738.5% during the 3rd quarter. Wedbush Securities Inc. now owns 97,430 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 85,810 shares in the last quarter. Vanguard Group Inc. grew its position in shares of KemPharm by 134.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 767,100 shares in the last quarter. BlackRock Inc. grew its position in shares of KemPharm by 21.7% during the 2nd quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock valued at $186,000 after purchasing an additional 19,001 shares in the last quarter. Iowa State Bank grew its position in shares of KemPharm by 90.6% during the 2nd quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 21,000 shares in the last quarter. Finally, RDA Financial Network purchased a new position in shares of KemPharm during the 2nd quarter valued at $28,000. Hedge funds and other institutional investors own 25.44% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Featured Article: Asset Allocation Models, Which is Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.